Very developed VERU-111, an oral, first-in-class alpha and beta tubulin inhibitor/cytoskeleton disruptor small molecule, for the treatment of COVID-19 patients at high risk for acute respiratory distress syndrome.
Rankings by 
National Ranking
453rd
in United StatesRegional Ranking
514th
in North America and CaribbeanGlobal Ranking
1245th
worldwide